Phase 2, Open-Label, Randomized, Multicenter Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Documented Infective Endocarditis
Latest Information Update: 27 Apr 2022
Price :
$35 *
At a glance
- Drugs Dalbavancin (Primary)
- Indications Bacterial endocarditis
- Focus Therapeutic Use
- Sponsors AbbVie
- 20 Oct 2017 Status changed from not yet recruiting to discontinued.
- 16 May 2017 New trial record